Medivir AB Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Medivir AB are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Medivir AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, Medivir AB is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Medivir |
Medivir AB Relative Risk vs. Return Landscape
If you would invest (100.00) in Medivir AB on September 28, 2025 and sell it today you would earn a total of 100.00 from holding Medivir AB or generate -100.0% return on investment over 90 days. Medivir AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded otc stocks are less volatile than Medivir, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Medivir AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medivir AB's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Medivir AB, and traders can use it to determine the average amount a Medivir AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MVRBF |
Based on monthly moving average Medivir AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medivir AB by adding Medivir AB to a well-diversified portfolio.
Medivir AB Fundamentals Growth
Medivir OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Medivir AB, and Medivir AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medivir OTC Stock performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 31.68 M | |||
| Shares Outstanding | 55.74 M | |||
| Price To Earning | 6.90 X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 26.57 X | |||
| Revenue | 25.54 M | |||
| EBITDA | (59.03 M) | |||
| Cash And Equivalents | 49.39 M | |||
| Cash Per Share | 2.09 X | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 1.96 X | |||
| Cash Flow From Operations | (48.73 M) | |||
| Total Asset | 335.82 M | |||
| Retained Earnings | 12 M | |||
| Current Asset | 1.06 B | |||
| Current Liabilities | 106 M | |||
Things to note about Medivir AB performance evaluation
Checking the ongoing alerts about Medivir AB for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Medivir AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medivir AB is not yet fully synchronised with the market data | |
| Medivir AB has some characteristics of a very speculative penny stock | |
| Medivir AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 25.54 M. Net Loss for the year was (63.12 M) with loss before overhead, payroll, taxes, and interest of (40.2 M). | |
| Medivir AB has accumulated about 49.39 M in cash with (48.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.09. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Medivir AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medivir AB's stock is overvalued or undervalued compared to its peers.
- Examining Medivir AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medivir AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medivir AB's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Medivir AB's otc stock. These opinions can provide insight into Medivir AB's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Medivir AB information on this page should be used as a complementary analysis to other Medivir AB's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Medivir OTC Stock
If you are still planning to invest in Medivir AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medivir AB's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |